Abstract 11176: SGLT-2-inhibition With Dapagliflozin Reduces Tissue Sodium Content
Introduction: Sodium tissue content by 23Na magnetic resonance imaging (Na-MRI) has been validated in experimental and human studies. SGLT-2 inhibition blocks the reabsorption of glucose and, in parallel, of sodium in the proximal tubular cells in a 1:1 fashion. We hypothesized that SGLT-2 inhibition in patients with type 2 diabetes leads to decreased tissue sodium content due to its pharmacological action.
Methods: In a prospective, double blind, placebo controlled, cross-over trial 59 patients (61±7.6 years) with type 2 diabetes were randomized to dapagliflozin 10 mg o.d. and placebo for 6 weeks each. In addition to metabolic parameters and ambulatory blood pressure (BP) we analyzed the sodium content in the skin and muscles of the lower leg by the Na-MRI at baseline, after the first and second treatment phase of 6 weeks.
Results: Compared to baseline 6 weeks treatment with the SGLT-2 inhibitor dapagliflozin decreased fasting (132±28 vs. 114±19mg/dl, p<0.001), postprandial blood glucose (178±66 mg/dl vs. 153±46mg/dl, p<0.001), body weight (87.6 vs. 86.6 kg, p<0.001) and systolic (129±12 vs. 126±11, p=0.010) and diastolic (77.4±9 vs. 75.6±8 mmHg, p=0.024) 24-hour ambulatory BP. Tissue sodium content in the skin was reduced after 6 weeks treatment with dapagliflozin compared to baseline (24.1±6.6 vs.22.7±6.4 mmol/L; p=0.013). No significant reduction of tissue sodium content was observed in the muscle (M. triceps surae: 20.5±3.5 vs. 20.4± 3.7 mmol/L, p=0.801). No clear significant difference in tissue water content of muscle and skin was observed after 6 weeks of treatment with dapagliflozin, compared to baseline.
Conclusions: SGLT-2 inhibition with dapagliflozin resulted in a significant decrease in sodium tissue content of the skin after 6 weeks. This observation point to a decrease of total sodium content in patients with type 2 diabetes known to be salt sensitive and prone to cardiovascular complications, that might be mitigated by SGLT-2 inhibition.The Study was supported by AstraZeneca.
Author Disclosures: R. Schmieder: Research Grant; Modest; AstraZeneca. Speakers Bureau; Modest; AstraZeneca. C. Ott: None. P. Linz: None. A. Jumar: None. S. Friedrich: None. J. Titze: None. M. Hammon: None. M. Uder: None. I. Kistner: None.
- © 2016 by American Heart Association, Inc.